The extracellular domain (ECD) of HER2 is the target of current monoclonal antibody (mAb) treatments for HER2+ breast cancer, including Trastuzumab (Herceptin®) and Pertuzumab (Perjeta®). Here, ERBB2 is linked to breast carcinoma.